Estimate first 11 patients ( 2 crs and hopefully 2 or more to go) by mid 2019 or earlier.
Upon success, then the addition 7 patients a following 9-12 months.
If 4 or more CRS are reported in the first stage of the trial, will be interesting to see if ink on paper results from a sponsorship.
Ovarian cancer results first I think.
As mentioned (Ann), modifications not unlike those with the extended arm resulting from the AML 1b results, are already in place and dosage at second level.
As far as scientific competence goes, we are in great hands (IMO)..,
Time will tell how good the science itself is.
Personally, willing to wait.
PTX Price at posting:
7.4¢ Sentiment: Buy Disclosure: Held
